natgillin/translations-raw huggingface dataset:
The portion of 13CO2 in the breath samples is determined by non-dispersive infrared spectrometry and stated as an absolute difference (-value) between the 00-minute- and the 30-minute-values.
Delež 13CO2 v izdihanem zraku je določen z nedisperzivno infrardečo spektrometrijo (NDIR, non-dispersive infrared spectrometry) in predstavljen kot absolutna razlika (vrednost Δδ) med 00-minutnimi in 30- minutnimi vrednostmi.
The positive benefit risk ratio for TAC compared to FAC remained unchanged
Ugodno razmerje koristi in tveganja za TAC v primerjavi s FAC je ostalo nespremenjeno.
The positive effect on PFS was seen across the subgroups of age (above or below 65 years), sex, race, histological subtype, geographic region, and those who received 0 or 1 prior VEGF/VEGFR-targeted therapy.
Pozitivni učinek na PFS je bil viden v podskupinah po starosti (več ali manj kot 65 let), spolu, rasi, histološki podvrsti, zemljepisni regiji in tistih, ki so prejeli 0 ali 1 predhodno zdravljenje, usmerjeno v VEGF/VEGFR.
The positive predictive value of strong fluorescence was higher (100.0 %; 90 % CI: 91.1 %-100.0 %) than of weak fluorescence (83.3 %; 90 % CI: 68.1 %-93.2 %).
Pozitivna napovedna vrednost močne fluorescence je bila večja (100,0 %; 90 % IZ: 91,1–100,0 %) od pozitivne napovedne vrednosti šibke fluorescence (83,3 %; 90 % IZ: 68,1–93,2 %).
The posology and administration schedule should be individualised.
Odmerjanje in shema uporabe morata biti prilagojeni posamezniku.
The posology in adolescents above the age of 12 years is the same as in adults (see section 5.1 and 5.2).
Odmerjanje pri mladostnikih, starejših od 12 let, je enako kot pri odraslih (glejte poglavji 5.1 in 5.2).
The posology in children and adolescents (0-18 years) is not different from that of adults as the posology for each indication is given by body weight and adjusted to the clinical outcome of the above mentioned conditions.
Odmerjanje pri otrocih in mladostnikih (0 – 18 let) se ne razlikuje od odmerjanja pri odraslih, saj je odmerjanje za posamezne indikacije navedeno po telesni masi in prilagojeno kliničnemu izidu zgoraj navedenih bolezni.
The posology in children and adolescents (2-18 years) is not different to that of adults as the posology for each indication is given by body weight and adjusted to the clinical outcome of the above mentioned conditions.
Odmerjanje pri otrocih in mladostnikih (2–18 let) se ne razlikuje od odmerjanja pri odraslih, saj se za posamezno indikacijo določa glede na telesno maso in se prilagaja glede na klinični izid zgoraj omenjenih stanj.
The posology in children and adolescents (2-18) is not different to that of adults as the posology for each indication is given by body weight and adjusted to the clinical outcome of the above mentioned conditions.
Odmerjanje pri otrocih in mladostnikih (2–18) se ne razlikuje od odmerjanja pri odraslih, saj se za posamezno indikacijo določa glede na telesno maso in se prilagaja glede na klinični izid zgoraj omenjenih stanj.
The posology is the same in adults and children.
Odmerjanje je enako za odrasle in otroke.
The posology of Soliris for PNH patients less than 40kg weight is based on the posology used for patients with aHUS and who weigh less than 40kg.
Odmerjanje zdravila Soliris za bolnike s PNH s telesno maso manj kot 40 kg temelji na odmerjanju, ki ga uporabljamo za bolnike z aHUS, ki tehtajo manj kot 40 kg.
The possibility exists for TNF-blocking agents, including Simponi, to affect host defences against infections and malignancies since TNF mediates inflammation and modulates cellular immune responses.
Obstaja možnost, da bodo zaviralci TNF, vključno z zdravilom Simponi, vplivali na obrambo osebe proti okužbam in malignim boleznim, ker je TNF mediator vnetja in spremeni celični imunski odziv.
The possibility of allergic reactions to substances contained in this medication, e.g. trace amounts of mouse and hamster protein exists in certain predisposed patients.
Pri nekaterih bolnikih, ki so nagnjeni k temu, obstaja možnost pojava alergijskih reakcij na snovi, ki jih vsebuje zdravilo, npr. na sledove beljakovin miši in hrčkov.
The possibility of an interaction cannot be excluded and a close monitoring of blood concentrations of ciclosporin, mycophenolate mofetil and tacrolimus should be considered during the use of combination and after its withdrawal.
Možnosti medsebojnega delovanja ni mogoče izključiti, zato je treba razmisliti o skrbnem nadziranju koncentracij ciklosporina, mikofenolata mofetila in takrolimusa v krvi v času uporabe te kombinacije in po prekinitvi.
The possibility of erroneous results may be minimised by drawing samples for PT or INR testing near the time of trough plasma concentrations of daptomycin (see section 4.4).
Verjetnost napačnih rezultatov zmanjšamo tako, da vzorce za določitev PČ ali INR vzamemo, ko pričakujemo padec koncentracije daptomicina v plazmi (glejte poglavje 4.4).
The possibility of hypersensitivity including severe life-threatening fatal anaphylactic / anaphylactoid reactions must always be considered.
Vedno je treba upoštevati možnost preobčutljivosti, vključno s hudimi smrtno nevarnimi anafilaktičnimi/anafilaktoidnimi reakcijami.
The possibility of interactions with other medicinal products administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system e.g. trimethoprim.
Treba je upoštevati možnost interakcij z drugimi zdravili, ki se uporabljajo sočasno, še posebno, če je njihova glavna pot izločanja aktivna renalna sekrecija prek organskega kationskega transportnega sistema, na primer s trimetoprimom.
The possibility of occurrence of autoimmune disorders in treated animals cannot therefore be ruled out and has to be balanced with the risk associated with FeLV/FIV infections.
Zaradi tega možnosti pojava avtoimunskih bolezni pri zdravljenih živalih ni mogoče izključiti in jo moramo oceniti tveganje, ki ga predstavljata okužbi s FeLV/FIV .
The possibility of occurrence of autoimmune disorders in treated animals cannot therefore be ruled out and has to be balanced with the risk associated with FeLV/FIV infections.
Zaradi tega možnosti pojava avtoimunskih bolezni pri zdravljenih živalih ni mogoče izključiti in moramo oceniti tveganje , ki ga predstavljata okužbi s FeLV/FIV .
The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving bisphosphonates who present with ear symptoms including chronic ear infections t.
Možnost osteonekroze zunanjega slušnega kanala je treba upoštevati pri bolnikih, ki prejemajo bisfosfonate in pri katerih se pojavljajo simptomi bolezni ušesa, vključno s kroničnimi vnetji ušesa.
The possibility of sevoflurane triggering episodes of malignant hyperthermia in susceptible dogs cannot be ruled out.
Ni mogoče izključiti možnosti, da bi sevofluran pri dovzetnih psih sprožil epizode maligne hipertermije.
The possibility of sevoflurane triggering episodes of malignant hyperthermia in susceptible dogs cannot be ruled out.
Čeprav ne poročajo o primerih maligne hipertermije pri psih pod anestezijo s sevofluranom, ni mogoče izključiti možnosti, da bi sevofluran pri dovzetnih psih sprožil epizode maligne hipertermije.
The possibility of this happening may increase if Xenical is taken with a diet high in fat.
Jemanje zdravila Xenical s hrano, ki ima veliko vsebnost maščob, poveča možnost teh dogodkov.
The possibility that abacavir increases the risk of having a heart attack cannot be excluded.
Možnosti, da abakavir poveča tveganje za srčni infarkt, ni mogoče izključiti.
The possibility that plerixafor in conjunction with G-CSF can cause splenic enlargement cannot be excluded.
Možnosti, da bi lahko jemanje pleriksaforja skupaj z G-CSF povzročilo povečanje vranice, ni mogoče izključiti.
The possibility to consider shortening treatment duration to 24 weeks in genotype 1 and 4 patients was examined based on a sustained rapid virological response observed in patients with rapid virological response at week 4 in studies NV15942 and ML17131 (see Table 14).
Možnost zmanjšanja trajanja zdravljenja na 24 tednov pri bolnikih z genotipoma 1 in 4 so proučevali na osnovi trajnega virološkega odziva, ki so ga opazili pri bolnikih s hitrim virološkim odzivom v 4. tednu v kliničnih preskušanjih NV15942 in ML17131 (glejte preglednico 14).
the possible effects of changing to different time zones,
možni vplivi spremembe časovnih con,
the possible effects of changing to different time zones,
možni vplivi spremembe časovnih pasov,
The possible effects of changing to different time zones.
O možnih vplivih spremembe časovnih con.
The possible exposure increase of certain CYP3A4 substrates (e.g. midazolam, triazolam, atorvastatin, lovastatin, simvastatin, astemizol, bepridil, cisaprid, dofetilid, levacetylmethadol, mizolastin, pimozid, quinidine, sertindol, terfenadin, dihydroergotamine, ergometrin, ergotamine, methylergometrine, eletriptan, nisoldipin and ranolazine) is unknown.
Morebitno povečanje izpostavljenosti nekaterim substratom CYP3A4 (npr. midazolamu, triazolamu, atorvastatinu, lovastatinu, simvastatinu, astemizolu, bepridilu, cisapridu, dofetilidu, levacetilmetadolu, mizolastinu, pimozidu, kinidinu, sertindolu, terfenadinu, dihidroergotaminu, ergometrinu, ergotaminu, metilergometrinu, eletriptanu, nisoldipinu in ranolazinu) ni znano.
the possible problems of changing to different time zones,
možne težave zaradi spremembe časovnih con,
The possible risk of enhanced RSV infection in the season following the season in which the patients were treated with palivizumab has not been conclusively ruled out by studies performed aiming at this particular point.
Posebej usmerjene raziskave niso dokončno ovrgle možnega tveganja za stopnjevano okužbo z RSV v sezonah po tisti, med katero bolniki dobijo palivizumab.
The possible risk of enhanced RSV infection in the season following the season in which the patients were treated with palivizumab has not been conclusively ruled out by studies performed aiming at this particular point.
Posebej usmerjene raziskave niso dokončno ovrgle možnega tveganja za stopnjevano sezonsko okužbo z RSV v sezonah po tisti, med katero bolniki dobijo palivizumab.
The possible role of brinzolamide on corneal endothelial function has not been investigated in patients with compromised corneas (particularly in patients with low endothelial cell count).
Morebitnega vpliva brinzolamida na delovanje roženičnega endotelija še niso raziskovali pri bolnikih z okvaro roženice (posebno pri tistih z majhnim številom endotelijskih celic).
The possible side effects of an overdose of Keppra are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.
Možni neželeni učinki pri prevelikem odmerjanju zdravila Keppra so zaspanost, agitacija (motorični nemir), agresivnost, zmanjšana budnost, upočasnitev dihanja in koma.
The possible side effects of an overdose of levetiracetam are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.
Možni neželeni učinki pri prevelikem odmerjanju levetiracetama so zaspanost, agitiranost, agresivnost, zmanjšana budnost, upočasnitev dihanja in koma.
The possible side effects of an overdose of Levetiracetam are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.
Možni neželeni učinki pri prevelikem odmerjanju zdravila Levetiracetam Accord so zaspanost, agitacija (motorični nemir), agresivnost, zmanjšana budnost, upočasnitev dihanja in koma.
The possible side effects of an overdose of Levetiracetam ratiopharm are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.
Možni neželeni učinki pri prevelikem odmerjanju zdravila Levetiracetam ratiopharm so zaspanost, agitacija (motorični nemir), agresivnost, zmanjšana budnost, upočasnitev dihanja in koma.
The possible side effects of an overdose of Matever are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.
Možni neželeni učinki pri prevelikem odmerjanju zdravila Matever so zaspanost, agitacija (motorični nemir), agresivnost, zmanjšana budnost, upočasnitev dihanja in koma.
The possible use of chelating therapies could interfere with the use of 64Cu-labelled medicinal products.
Morebitna uporaba kelatnih terapij lahko ovira uporabo z bakrom (64Cu) označenih zdravil.
The post- marketing safety experience with qHPV vaccine is relevant to Gardasil 9 since the vaccines contain L1 HPV proteins of 4 of the same HPV types.
Izkušnje v obdobju trženja glede varnosti qHPV cepiva so pomembne za cepivo Gardasil 9, ker to cepivo vsebuje protein L1 HPV štirih istih tipov HPV.
The postmarketing experience has shown that the most serious adverse reactions are Stevens-Johnson syndrome/ toxic epidermal necrolysis, serious hepatitis/hepatic failure, and drug reaction with eosinophilia and systemic symptoms, characterised by rash with constitutional symptoms such as fever, arthralgia, myalgia and lymphadenopathy, plus visceral involvement, such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction.
Izkušnje po pridobitvi dovoljenja za promet kažejo, da so najresnejši neželeni učinki Stevens- Johnsonov sindrom/toksična epidermalna nekroliza, hude oblike hepatitisa oz. jetrna odpoved in reakcija na zdravilo z eozinofilijo in sistemskimi simptomi, za katere sta značilna izpuščaj s splošnimi simptomi, kot so vročina, artralgija, mialgija in limfadenopatija, in prizadetost visceralnih organov, ki se kaže kot hepatitis, eozinofilija, granulocitopenija in motnje ledvične funkcije.
The potassium content per infusion should be taken into account if administered to patients with renal impairment and/or those on a controlled potassium diet.
Vsebnost kalija na infuzijo je treba upoštevati pri dajanju zdravila bolnikom z ledvično okvaro in/ali tistim na dieti z nadziranim vnosom kalija.
The potency (IU) is determined using a method equivalent to the test method described in the European Pharmacopoeia.
Jakost (i.e.) je določena z metodo, ekvivalentno testni metodi, opisani v Evropski farmakopeji.
The potency (IU) is determined using the one-stage clotting assay against the FDA Mega standard which was calibrated against WHO standard in International Units (IU).
Jakost zdravila (i.e.) se določa z enostopenjskim testom strjevanja krvi, v primerjavi z FDA mega- standardom, ki je bil umerjen v mednarodnih enotah (i.e.) glede na standard SZO.
The potency of insulin analogues, including insulin degludec, is expressed in units (U).
Moč insulinskih analogov, tudi insulina degludek, izražamo v enotah (e.).
The potency of insulin analogues, including Ryzodeg is expressed in units (U).
Moč insulinskih analogov, tudi zdravila Ryzodeg, izražamo v enotah (e.).
The potency of this medicinal product should not be compared to the one of another pegylated or non- pegylated protein of the same therapeutic class.
Jakosti tega zdravila ne smete primerjati z jakostjo drugih pegiliranih ali nepegiliranih beljakovin iz istega terapevtskega razreda.
The potency of this product should not be compared to that of another pegylated or nonpegylated protein of the same therapeutic class (see section 5.1).
Jakosti tega zdravila se ne sme primerjati z jakostjo drugih pegiliranih ali nepegiliranih beljakovin iz istega terapevtskega razreda (glejte poglavje 5.1).
The potency of this product should not be compared to the one of another pegylated or non-pegylated protein of the same therapeutic class.
Jakosti tega zdravila ne smemo primerjati z jakostjo druge pegilirane ali nepegilirane beljakovine iz iste terapevtske skupine.
The potency of this product should not be compared to the potency of another pegylated or non- pegylated protein of the same therapeutic class.
Učinkovitost tega sredstva ne gre primerjati z učinkovitostjo drugih pegiliranih ali nepegiliranih proteinov iz iste terapevtske skupine.
The potency of this product should not be compared to the potency of another pegylated or non- pegylated protein of the same therapeutic class.
Učinkovitosti tega sredstva ne gre primerjati z učinkovitostjo drugih pegiliranih ali nepegiliranih proteinov iz iste terapevtske skupine.
The potency of this product should not be compared to the potency of another pegylated or non- pegylated protein of the same therapeutic class.
Učinkovitosti tega zdravila se ne sme primerjati z učinkovitostjo drugih pegiliranih ali nepegiliranih proteinov iz iste terapevtske skupine.
The potent effectiveness of erlotinib in blocking EGFR-mediated signalling in these EGFR mutation positive tumours is attributed to the tight binding of erlotinib to the ATP-binding site in the mutated kinase domain of the EGFR.
Trdni vezavi erlotiniba na vezavno mesto za ATP v mutirani kinazni domeni EGFR lahko pripišemo veliko učinkovitost erlotiniba pri blokadi z EGFR posredovanega signaliziranja v tumorjih z EGFR- aktivirajočimi mutacijami.
The potential benefit of stopping alpha1 blocking therapy prior to cataract surgery has not been established and must be weighed against the risk of stopping the antipsychotic therapy.
Možnih koristi ukinitve zdravljenja z zaviralci receptorjev alfa-1 pred operacijo sive mrene niso ugotovili in jih je treba pretehtati glede na tveganja ob ukinitvi antipsihotičnega zdravljenja.
The potential benefits to the mother and risks to the infant should be considered before administering Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals 3.75 µg during lactation.
Pred cepljenjem doječe matere s cepivom Prepandemično cepivo proti gripi (H5N1) (z delci virionov, inaktivirano, z adjuvansom) GlaxoSmithKline Biologicals 3,75 µg je treba presoditi o možnih koristih za mater in tveganjih za dojenega otroka.
The potential benefits to the mother and risks to the infant should be considered before administering Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics during breast-feeding.
Pred cepljenjem doječe matere s cepivom Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics je treba pretehtati moţne koristi za mater in tveganja za otroka
The potential cardiac risk: Daliresp has not been studied in patients in congestive heart failure (NYHA grade 3 and 4); hence, it is not recommended in this population.
Potencialno tveganje za srce: zdravilo Daliresp ni bilo raziskano pri bolnikih s kongestivnim srčnim popuščanjem (NYHA stopnje 3 in 4); za to populacijo ni priporočljiv.
The potential cardiac risk: Daxas has not been studied in patients in congestive heart failure (NYHA grade 3 and 4); hence, it is not recommended in this population.
Potencialno tveganje za srce: zdravilo Daxas ni bilo raziskano pri bolnikih s kongestivnim srčnim popuščanjem (NYHA stopnje 3 in 4); za to populacijo ni priporočljiv.
The potential clinical consequences of such interactions have not been investigated.
Možne klinične posledice takšnega medsedbojnega delovanja še niso raziskane.
The potential clinical significance of these findings is uncertain.
Klinični pomen teh izsledkov ni jasen.
The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these active substances with Akynzeo.
Pri midazolamu ali drugih benzodiazepinih, ki se presnavljajo prek CYP3A4 (alprazolam, triazolam), je treba ob sočasnem dajanju zdravila Akynzeo upoštevati možne učinke njihovih zvišanih plazemskih koncentracij.
The potential effects of plerixafor on male and female fertility and post-natal development have not been evaluated in non-clinical studies.
Možne vplive pleriksaforja na moško in žensko rodnost ter na postnatalni razvoj še niso ocenili v nekliničnih študijah.
The potential for dermal transfer of oxybutynin from a treated person to an untreated person was evaluated in a single-dose study where subjects dosed with Kentera engaged in vigorous contact with an untreated partner for 15 minutes, either with (N=14 couples) or without (N=12 couples) clothing covering the application area.
Možnost prenosa oksibutinina prek kože z zdravljene na nezdravljeno osebo so ocenili v študiji z enkratnim odmerkom, v kateri so bili preiskovanci, ki so prejeli zdravilo Kentera, 15 minut v aktivnem stiku z nezdravljenim partnerjem, z oblačili, ki so prekrivala mesto aplikacije (n = 14 parov) ali brez njih (n = 12 parov).
The potential for dermal transfer of oxybutynin from a treated person to an untreated person was evaluated in a single-dose study where subjects dosed with Kentera engaged in vigorous contact with an untreated partner for 15 minutes, either with (N=14 couples) or without (N=12 couples) clothing covering the application area.
Možnost prenosa oksibutinina prek kože z zdravljene na nezdravljeno osebo so ocenili v študiji z enkratnim odmerkom, v kateri so bili preizkušanci, ki so prejeli zdravilo Kentera, 15 minut v aktivnem stiku z nezdravljenim partnerjem, z oblačili, ki so prekrivala mesto aplikacije (n = 14 parov) ali brez njih (n = 12 parov).
The potential for dextromethorphan and quinidine to inhibit or induce cytochrome P450 in vitro were evaluated in human microsomes.
Potencial dekstrometorfana in kinidina za zaviranje ali indukcijo citokroma P450 in vitro je bil ocenjen na človeških mikrosomih.
The potential for drug-drug interactions with mepolizumab is therefore considered low.
Možnost za medsebojno delovanje zdravil z mepolizumabom je zato majhna.
The potential for grazoprevir to be a breast cancer resistance protein (BCRP) substrate cannot be excluded.
Možnosti, da je grazoprevir substrat za protein odpornosti pri raku dojke (BCRP – breast cancer resistance protein), ni mogoče izključiti.
the potential for increased adverse
lahko zveča možnost za neželene
The potential for inhibition of P-gp by mirabegron should be considered when Betmiga is combined with sensitive P-gp substrates e.g. dabigatran.
Če je zdravilo Betmiga uporabljeno v kombinaciji z občutljivimi substrati P-gp, npr. z dabigatranom, je treba upoštevati moţnost zavrtja P-gp z mirabegronom.
The potential for interactions between Vistide and anti-HIV protease inhibitors has not been studied.
Možni medsebojni učinki med zdravilom Vistide in zaviralci proteaz proti HIV niso raziskani.
The potential for lapatinib to prolong the QTc interval has not been ruled out (see section 4.4).
Ni izključeno, da lahko lapatinib podaljša interval QT (glejte poglavje 4.4).
The potential for olaparib to induce CYP2C9, CYP2C19 and
Prav tako ni mogoče izključiti možnosti, da olaparib inducira CYP2C9, CYP2C19 in
The potential for QT interval prolongation of ceritinib was assessed in four clinical studies with Zykadia.
Potencial ceritiniba za podaljševanje intervala QT so ocenjevali v štirih kliničnih študijah zdravila Zykadia.
The potential for surgical and clinical complications and how to respond in the event any such complications arise.
Možnostih za kirurške in klinične zaplete ter kako se odzvati, če se takšni zapleti pojavijo.
The potential for these events in patients with unstable and/or symptomatic brain metastases or low platelets (<75,000) is not established as patients with these conditions were excluded from clinical trials.
Možnost za takšne dogodke pri bolnikih z nestabilnimi in/ali simptomatskimi metastazami v možganih ali majhnim številom trombocitov (< 75.000) ni ugotovljena, ker so bili bolniki s temi stanji izključeni iz kliničnih preskušanj.
The potential impact of VEGFR inhibition by nintedanib and the anti-angiogenic activity of nintedanib on IPF pathology are currently not fully elucidated.
Možni vpliv zaviranja VEGFR z nintedanibom in antiangiogenska aktivnost nintedaniba na patologijo IPF trenutno niso povsem pojasnjeni.
The potential interactions of romiplostim with co- administered medicinal products due to binding to plasma proteins remain unknown.
Možna medsebojna delovanja romiplostima med sočasno uporabo drugih zdravil zaradi vezave na plazemske beljakovine ostajajo neznana.
The potential risk associated with retreatment with LEMTRADA following the occurrence of ITP is unknown.
Možno tveganje, povezano s ponovnim zdravljenjem z zdravilom LEMTRADA po pojavu ITP, ni znano.